{"filing":{"accession_number":"0001493152-26-042488","cik":"0002029039","ticker":"NSRX","company_name":"Nasus Pharma Ltd","form":"6-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2029039/000149315226042488/form6-k.htm"},"events":[{"id":33153,"run_id":30478,"accession_number":"0001493152-26-042488","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Nasus Pharma announced FDA clearance of its IND application for NS002, an investigational intranasal epinephrine powder for anaphylaxis treatment, and plans to initiate a pivotal clinical study in Q4 2026 with topline data expected in Q1 2027. This is a material regulatory and clinical milestone for a clinical-stage biopharmaceutical company, representing significant progress toward commercialization of a lead product candidate in a $2 billion market. While not fitting the specific event types (not an earnings release, M\u0026A activity, or executive change), this operational/regulatory milestone would materially affect a reasonable investor's assessment of the company's development pipeline and commercial prospects.","company_name":"Nasus Pharma Ltd","ticker":"NSRX","filing_date":"2026-09-14","form":"6-K","submitted_at":null,"items":[{"id":36522,"accession_number":"0001493152-26-042488","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Nasus Pharma announced FDA clearance of its IND application for NS002, an investigational intranasal epinephrine powder for anaphylaxis treatment, and plans to initiate a pivotal clinical study in Q4 2026 with topline data expected in Q1 2027. This is a material regulatory and clinical milestone for a clinical-stage biopharmaceutical company, representing significant progress toward commercialization of a lead product candidate in a $2 billion market. While not fitting the specific event types (not an earnings release, M\u0026A activity, or executive change), this operational/regulatory milestone would materially affect a reasonable investor's assessment of the company's development pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T12:15:55.336691+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36522,"accession_number":"0001493152-26-042488","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Nasus Pharma announced FDA clearance of its IND application for NS002, an investigational intranasal epinephrine powder for anaphylaxis treatment, and plans to initiate a pivotal clinical study in Q4 2026 with topline data expected in Q1 2027. This is a material regulatory and clinical milestone for a clinical-stage biopharmaceutical company, representing significant progress toward commercialization of a lead product candidate in a $2 billion market. While not fitting the specific event types (not an earnings release, M\u0026A activity, or executive change), this operational/regulatory milestone would materially affect a reasonable investor's assessment of the company's development pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T12:15:55.336691+00:00","company_name":"Nasus Pharma Ltd","ticker":"NSRX","filing_date":"2026-09-14"}]}